Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tamibarotene: Preliminary Phase II data

Preliminary data from the open-label, international pivotal Phase II STAR-1 trial in 11 relapsed/refractory patients who failed treatment with all-trans

Read the full 208 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE